These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 23901051)

  • 1. Phosphate control in end-stage renal disease: barriers and opportunities.
    Waheed AA; Pedraza F; Lenz O; Isakova T
    Nephrol Dial Transplant; 2013 Dec; 28(12):2961-8. PubMed ID: 23901051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
    Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
    Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon.
    Qunibi WY; Nolan CA; Ayus JC
    Kidney Int Suppl; 2002 Dec; (82):S73-80. PubMed ID: 12410860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperphosphatemia in end-stage renal disease.
    Indridason OS; Quarles LD
    Adv Ren Replace Ther; 2002 Jul; 9(3):184-92. PubMed ID: 12203200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salivary glands: a new player in phosphorus metabolism.
    Savica V; Calò LA; Santoro D; Monardo P; Santoro G; Muraca U; Davis PA; Bellinghieri G
    J Ren Nutr; 2011 Jan; 21(1):39-42. PubMed ID: 21195917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphate Binders and Targets Over Decades: Do We have it Right Now?
    Marcuccilli M; Chonchol M; Jovanovich A
    Semin Dial; 2017 Mar; 30(2):134-141. PubMed ID: 28064444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia.
    Savica V; Calò LA; Monardo P; Santoro D; Mallamace A; Muraca U; Bellinghieri G
    J Ren Nutr; 2009 Jan; 19(1):69-72. PubMed ID: 19121775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
    Malberti F
    G Ital Nefrol; 2010; 27 Suppl 52():S47-54. PubMed ID: 21132662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in Hyperphosphatemia Using Phosphate Education and Planning Talks.
    Brauer A; Waheed S; Singh T; Maursetter L
    J Ren Nutr; 2019 Mar; 29(2):156-162. PubMed ID: 30087012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Directions in Phosphorus Management in Dialysis.
    Dwyer JP; Kelepouris E
    J Ren Nutr; 2023 Jan; 33(1):12-16. PubMed ID: 35597321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary management of phosphorus retention in chronic kidney disease: a review.
    Amiri FS
    Clin Exp Nephrol; 2015 Dec; 19(6):985-99. PubMed ID: 26032778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.
    Shigematsu T; Ohya M; Negi S; Masumoto AR; Nakashima YM; Iwatani Y; Moribata MK; Yamanaka S; Tatsuta K; Mima T
    Contrib Nephrol; 2015; 185():42-55. PubMed ID: 26023014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphate: a stealthier killer than previously thought?
    Gonzalez-Parra E; Tuñón J; Egido J; Ortiz A
    Cardiovasc Pathol; 2012; 21(5):372-81. PubMed ID: 22425627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical management of hyperphosphatemia.
    Ritz E
    J Nephrol; 2005; 18(3):221-8. PubMed ID: 16013007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.
    Nolan CR; Qunibi WY
    Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):373-9. PubMed ID: 12815333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of nicotinamide to treat hyperphosphatemia in dialysis patients.
    Lenglet A; Liabeuf S; Guffroy P; Fournier A; Brazier M; Massy ZA
    Drugs R D; 2013 Sep; 13(3):165-73. PubMed ID: 24000048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.
    Locatelli F; Del Vecchio L; Violo L; Pontoriero G
    Expert Opin Drug Saf; 2014 May; 13(5):551-61. PubMed ID: 24702470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.